Investors need to pay close attention to EW stock based on the movements in the options market lately.

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]

Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...

SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls

Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Moby summary of Edwards Lifesciences Corporation's Q2 2026 earnings call

An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.

Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.

Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products. Chief Executive Officer Bernard Zovighian said the

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.

EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.

The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.

(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig

The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.